[go: up one dir, main page]

PT904081E - Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona - Google Patents

Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona

Info

Publication number
PT904081E
PT904081E PT97923912T PT97923912T PT904081E PT 904081 E PT904081 E PT 904081E PT 97923912 T PT97923912 T PT 97923912T PT 97923912 T PT97923912 T PT 97923912T PT 904081 E PT904081 E PT 904081E
Authority
PT
Portugal
Prior art keywords
aquos
suspensions
fatty acids
acids esters
hydroxyrisperidone fatty
Prior art date
Application number
PT97923912T
Other languages
English (en)
Inventor
Roger Carolus August Embrechis
Marc Karel Jozef Francois
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT904081(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT904081E publication Critical patent/PT904081E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT97923912T 1996-05-20 1997-05-12 Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona PT904081E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (1)

Publication Number Publication Date
PT904081E true PT904081E (pt) 2002-04-29

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97923912T PT904081E (pt) 1996-05-20 1997-05-12 Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona

Country Status (38)

Country Link
US (1) US6077843A (pt)
EP (1) EP0904081B1 (pt)
JP (1) JP3274687B2 (pt)
KR (1) KR100358373B1 (pt)
CN (1) CN1093762C (pt)
AR (1) AR007194A1 (pt)
AT (1) ATE208619T1 (pt)
AU (1) AU715572B2 (pt)
BG (1) BG62684B1 (pt)
BR (1) BR9706824B8 (pt)
CA (1) CA2236691C (pt)
CY (2) CY2270B1 (pt)
CZ (1) CZ291284B6 (pt)
DE (2) DE122011100027I1 (pt)
DK (1) DK0904081T3 (pt)
EA (1) EA000536B1 (pt)
EE (1) EE03594B1 (pt)
ES (1) ES2167745T3 (pt)
FR (1) FR11C0035I2 (pt)
HK (1) HK1017852A1 (pt)
HR (1) HRP970276B1 (pt)
HU (2) HU224025B1 (pt)
ID (1) ID16927A (pt)
IL (1) IL124551A (pt)
LU (1) LU91842I2 (pt)
MX (1) MX9804816A (pt)
MY (1) MY126302A (pt)
NO (2) NO315931B1 (pt)
NZ (1) NZ330369A (pt)
PL (1) PL188309B1 (pt)
PT (1) PT904081E (pt)
SI (1) SI0904081T1 (pt)
SK (1) SK284013B6 (pt)
TR (1) TR199800923T2 (pt)
TW (1) TW487572B (pt)
UA (1) UA61898C2 (pt)
WO (1) WO1997044039A1 (pt)
ZA (1) ZA974331B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE265846T1 (de) * 1998-02-25 2004-05-15 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
DE60024981T2 (de) 1999-03-31 2006-09-14 Janssen Pharmaceutica N.V. Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PT1783118E (pt) * 2000-08-14 2008-08-19 Teva Pharma Preparação de risperidona
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CA2494234C (en) * 2002-07-29 2009-10-27 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
JP5306599B2 (ja) * 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
US8221778B2 (en) * 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
CN101641353B (zh) * 2007-04-19 2012-05-23 长春健欣生物医药科技开发有限公司 用于治疗精神疾病的新颖化合物及其制备方法和用途
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
ES2868353T3 (es) * 2007-12-19 2021-10-21 Janssen Pharmaceutica Nv Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción
WO2009089076A2 (en) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of paliperidone palmitate
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN102164597B (zh) 2008-09-04 2014-09-03 安米林药品有限责任公司 使用非水性载体的持续释放制剂
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
BR112012010195A2 (pt) 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN107595771A (zh) 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2683717T3 (pl) * 2011-05-31 2016-11-30 Wytwarzanie 3-[2-[4-((6-fluoro-1,2-benzoizoksazol-3-ilo)-1-piperydynylo)-6,7,8,9-tetrahydro-9- hydroksy-2-metylo-4H-pirydo[1,2-a]pirymidyn-4-onu (paliperydonu) i palmitynianu paliperydonu
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
HRP20240022T1 (hr) 2015-04-07 2024-03-29 Janssen Pharmaceutica Nv Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
IL303253A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
LT4025187T (lt) 2020-11-30 2024-02-12 Janssen Pharmaceutica Nv Dozavimo režimai, susiję su prailginto atpalaidavimo injekcinėmis paliperidono vaisto formomis
RS65815B1 (sr) 2020-11-30 2024-08-30 Janssen Pharmaceutica Nv Režimi doziranja povezani sa formulacijama za injektovanje paliperidona sa produženim oslobađanjem
HUE067584T2 (hu) 2020-11-30 2024-10-28 Janssen Pharmaceutica Nv Eljárások paliperidon-palmitát formulációk reszuszpenziójának biztosítására
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN118119394A (zh) 2021-08-20 2024-05-31 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE69434258T2 (de) * 1993-11-19 2006-01-19 Janssen Pharmaceutica N.V. Mikroverkapselte 1,2-benzazole
PT729353E (pt) * 1993-11-19 2002-07-31 Alkermes Inc Preparacao de microparticulas biodegradaveis contendo um agente biologicamente activo
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP0833820B1 (en) * 1995-06-06 2001-02-14 Aventis Pharmaceuticals Inc. Benzisoxazole and indazole derivatives as antipsychotic agents
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
TW487572B (en) 2002-05-21
SK284013B6 (sk) 2004-08-03
BR9706824B8 (pt) 2015-02-18
HRP970276A2 (en) 1998-04-30
NO2011015I1 (no) 2011-09-19
HUS1100013I1 (hu) 2017-03-28
CZ140198A3 (cs) 1999-04-14
CY2011011I2 (el) 2016-12-14
HUP9901319A3 (en) 1999-11-29
ATE208619T1 (de) 2001-11-15
KR19990067603A (ko) 1999-08-25
BG62684B1 (bg) 2000-05-31
NO981984D0 (no) 1998-04-30
WO1997044039A1 (en) 1997-11-27
US6077843A (en) 2000-06-20
SK62098A3 (en) 2000-04-10
CN1206347A (zh) 1999-01-27
HK1017852A1 (en) 1999-12-03
JP3274687B2 (ja) 2002-04-15
TR199800923T2 (xx) 1999-09-21
KR100358373B1 (ko) 2003-02-11
EA000536B1 (ru) 1999-10-28
EE9800136A (et) 1998-10-15
AU2955997A (en) 1997-12-09
MX9804816A (es) 1998-10-31
CY2270B1 (en) 2003-07-04
UA61898C2 (en) 2003-12-15
EA199800531A1 (ru) 1998-12-24
AU715572B2 (en) 2000-02-03
NZ330369A (en) 2000-04-28
PL188309B1 (pl) 2005-01-31
ES2167745T3 (es) 2002-05-16
BR9706824A (pt) 1999-03-23
CA2236691C (en) 2007-01-02
FR11C0035I1 (pt) 2011-07-10
NO2011015I2 (no) 2013-03-11
HUP9901319A2 (hu) 1999-08-30
FR11C0035I2 (fr) 2013-08-16
SI0904081T1 (en) 2002-04-30
DE69708284T2 (de) 2002-07-25
CZ291284B6 (cs) 2003-01-15
DK0904081T3 (da) 2002-02-25
EE03594B1 (et) 2002-02-15
AR007194A1 (es) 1999-10-13
DE122011100027I1 (de) 2011-11-17
CA2236691A1 (en) 1997-11-27
BG102443A (en) 1999-06-30
ZA974331B (en) 1998-11-19
EP0904081B1 (en) 2001-11-14
NO315931B1 (no) 2003-11-17
DE69708284D1 (de) 2001-12-20
IL124551A0 (en) 1998-12-06
MY126302A (en) 2006-09-29
CN1093762C (zh) 2002-11-06
IL124551A (en) 2001-08-26
PL327995A1 (en) 1999-01-04
ID16927A (id) 1997-11-20
HRP970276B1 (en) 2002-04-30
EP0904081A1 (en) 1999-03-31
CY2011011I1 (el) 2016-12-14
LU91842I2 (fr) 2011-09-20
JP2000513718A (ja) 2000-10-17
HU224025B1 (hu) 2005-05-30
NO981984L (no) 1998-11-19

Similar Documents

Publication Publication Date Title
PT904081E (pt) Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona
PT1033987E (pt) Suspensoes aquosas de esteres de 9-hidroxirrisperidona com acidos gordos da ordem dos submicrons
PL331700A1 (en) Method of obtaining fatty acid esters
EP0736545A3 (en) Ester of dextrin and fatty acids and its use
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
PL371212A1 (en) Method and system for the esterification of fatty acids
ID17964A (id) Pembuatan ester surfaktan
EE04281B1 (et) 8-metoksükinoloonkarboksüülhapete valmistamismeetod
DK0718275T3 (da) Kvaternære triethanolaminfedtsyreestere
DE69507006D1 (de) Ceramid-3-derivate von einfachungesättigten fettsäuren
GB9620248D0 (en) Esters of unsaturated fatty acids
PL332853A1 (en) Method of obtaining alpha-alkoxy-alpha-trifluoromethyl-acrylacetic esters and acids
PT854142E (pt) Processo para preparacao de esteres de acidos 1-alquilpirazol-5-carboxilicos
GB9805123D0 (en) Presentation of fatty acids
ATE221519T1 (de) Ester von 3-hydroxy-piperidinmethanol-derivaten
DE69515479D1 (de) Fettsäureester von verätherten polyalkoholen
BR9703374A (pt) Misturas tensoativas de acilovialcanossulfonatos e ésteres de ácidos graxos
AU3645195A (en) Modified polyunsaturated fatty acids
GB9517107D0 (en) Fatty acid esters
PL322156A1 (en) Method of obtaining monocarboxylic esters
ATA199097A (de) Verfahren zur herstellung von fettsäuremethylester und anlage zur durchführung des verfahrens
GB9317347D0 (en) Method of maintaining the level of polyunsaturated fatty acids
PL331949A1 (en) Method of obtaining methyl esters of fatty acids
PL310213A1 (en) Method of obtaining benzoic esters